NextCure, Inc. (NXTC)
| Market Cap | 194.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -66.35M |
| Shares Out | 27.61M |
| EPS (ttm) | -2.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,288 |
| Open | 6.85 |
| Previous Close | 6.89 |
| Day's Range | 6.80 - 7.10 |
| 52-Week Range | 6.70 - 14.40 |
| Beta | -0.51 |
| Analysts | Buy |
| Price Target | 17.57 (+149.2%) |
| Est. Earnings Date | Nov 4, 2021 |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1;...
Financial Performance
In 2020, NextCure's revenue was $22.38 million, an increase of 252.58% compared to the previous year's $6.35 million. Losses were -$36.60 million, 8.50% more than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NextCure stock is "Buy." The 12-month stock price forecast is 17.57, which is an increase of 149.22% from the latest price.
News
NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings
NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-labe...
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat can...
NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies
NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tu...
NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat can...
NextCure to Present at the JMP Securities Life Sciences Conference
BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annu...
BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...
NextCure Reports First Quarter 2021 Financial Results
BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...
NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference
BELTSVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...
NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit
BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
NextCure to Host Virtual R&D Update Event on March 4, 2021
BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
LONG-TERM INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. a...
Los Angeles, California--(Newsfile Corp. - February 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....
LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, ...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.
Dr. Han Myint Appointed as NextCure's Chief Medical Officer
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “th...
NextCure Provides Updates on NC318 Clinical Program
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
NextCure (NXTC) in Focus: Stock Moves 7.6% Higher
NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. - NXTC
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact...